amlitelimab

News

Sanofi slumps despite positive eczema drug readout

Shares in Sanofi have fallen after it reported data from a phase 3 trial of atopic dermatitis drug amlitelimab – even though it met all objectives.

News

Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma

Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.

News

AAD: Sanofi showcases data on possible Dupixent successor

Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD) after reporting new phase 2

News

Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e...

Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category earlier this year when it

Sanofi slumps despite positive eczema drug readout

Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma

AAD: Sanofi showcases data on possible Dupixent successor

Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

amlitelimab

Editor's Picks